Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients
- 2.5k Downloads
Despite extensive effort on studying inflammatory processes in the CNS of Parkinson’s disease (PD) patients, implications of peripheral monocytes are still poorly understood. Here, we set out to obtain a comprehensive picture of circulating myeloid cells in PD patients. We applied a human primary monocyte culture system and flow cytometry-based techniques to determine the state of monocytes from PD patients during disease. We found that the classical monocytes are enriched in the blood of PD patients along with an increase in the monocyte-recruiting chemoattractant protein CCL2. Moreover, we found that monocytes from PD patients display a pathological hyperactivity in response to LPS stimulation that correlates with disease severity. Inflammatory pre-conditioning was also reflected on the transcriptome in PD monocytes using next-generation sequencing. Further, we identified the CD95/CD95L as a key regulator for the PD-associated alteration of circulating monocytes. Pharmacological neutralization of CD95L reverses the dysregulation of monocytic subpopulations in favor of non-classical monocytes. Our results suggest that PD monocytes are in an inflammatory predisposition responding with hyperactivation to a “second hit”. These results provide the first direct evidence that circulating human peripheral blood monocytes are altered in terms of their function and composition in PD patients. This study provides insights into monocyte biology in PD and establishes a basis for future studies on peripheral inflammation.
KeywordsParkinson’s disease Blood monocytes Inflammation CCL2 FAS/FASLG
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease characterized by a progressive loss of neurons in the substantia nigra and other brain regions. However, the underlying pathomechanisms leading to neuronal death are currently unknown. While several mechanisms (e.g., protein aggregation, mitochondrial dysfunction and others) have been discussed as potential pathophysiological pathways, emerging evidence indicates that the immune system also plays a critical role in the pathogenesis of PD. For example, CNS neuroinflammation is recognized as a hallmark in PD  and genome-wide association studies have linked polymorphisms in immune genes as risk factors for PD . In contrast to the wealth of studies on neuroinflammatory processes in the CNS of PD patients (see review ), the particular state of the peripheral innate immune system during PD is not understood. To date, some studies have shown elevated levels of serum cytokines (IL-2, IL-4, IL-6, IL-10, TNFα) in PD patients [11, 35, 40] as first general evidence of immune dysregulation. Specifically, peripheral blood mononuclear cells (PBMCs) are suspected to contribute to peripheral cytokine elevation but conclusive evidence in humans is largely missing. In an animal model for PD  and other neurodegenerative diseases [2, 9, 38], invasion of peripheral monocytes into the CNS has been demonstrated. Butovsky et al.  have clearly shown that monocytes which migrate into the mouse CNS are a distinct functional entity with different functional properties than CNS-resident microglia. Peripherally activated monocytes could thus have a tremendous impact on CNS inflammation but the existence and mode of peripheral innate inflammation in PD patients remain unclear to date.
In mice, two subsets of circulating monocytes based on their differential expression of CCR2 and CX3CR1 can be distinguished. The so-called “inflammatory monocytes” (Ly6ChiCCR2-highCx3CR1low) with a pronounced pro-inflammatory cytokine profile are highly mobile and rapidly recruited to inflamed tissue. They can be differentiated from “resident” monocytes (Ly6CloCCR2lowCX3CR1high) that are important for regeneration and patrol along blood vessels [4, 24, 36]. Interestingly, recruitment of Ly6Chi monocytes into the inflamed CNS has previously been reported in mouse models [10, 32]. In humans, equivalent subsets of monocytes can be distinguished based on the expression of CD14 and CD16. In detail, Ly6Chi and LyC6lo correspond to CD14+CD16− and CD14+CD16+ and are known as “classical” and “non-classical” monocytes, respectively .
Little is known about how different monocyte subpopulations are balanced in humans. The FAS/FAS ligand (FASLG) system can contribute to inflammatory reactions by mediating the release of cytokines from myeloid cells  and triggering the recruitment of peripheral monocytes and macrophages to the site of inflammation [5, 12]. Upregulation of FASLG expression in peripheral blood myeloid cells in rodents and in humans was found to be required for the recruitment of peripheral myeloid cells to the injured tissue. FASLG contributes to neuronal cell loss by regulating the differentiation and function of peripheral myeloid cells, rather than via direct FAS-induced apoptosis in FAS-bearing neural cells . Even though there have been studies on the FAS/FASLG system in the context of apoptosis and PD in animal models [20, 28, 30], its involvement in inflammation and dysregulation in PD patients is still elusive. Specifically, the effect of FASLG on myeloid cells in the periphery and its potential role in the regulation of different monocyte subpopulations in humans have not yet been investigated.
Therefore, the aim of this study was a comprehensive characterization of circulating myeloid cells of PD patients and to understand their particular state during PD. Using a primary model for human monocytes, we examined the correlation between human monocyte functionality and clinical features of PD. We applied next-generation sequencing to explore the transcriptome of PD monocytes compared to age-matched healthy controls. We further studied the involvement of the FAS/FASLG system in monocyte regulation in PD and assessed its therapeutic consequences on monocyte function.
Materials and methods
All chemicals used were purchased from Sigma Aldrich (Munich, Germany) unless stated otherwise.
Ethical approval and study cohort
All human experiments were performed in accordance with the declaration of Helsinki and approved by the Ethics Committee of Ulm University. All study participants gave informed written consent to participate in the study.
PD patients as well as healthy controls were recruited at the University and rehab hospital Ulm (RKU). Healthy controls were chosen to match the patient cohort’s characteristics. A detailed description of the patient cohort for each experiment can be found as Supplementary Tables 1–5. In general, PD patients with confounding factors affecting the immune system were excluded for all experiments. PD patients with other co-morbidities like hypertension or depression were included in the study (see Supplementary Tables 1–5). All PD patients included in the study were diagnosed using the UK PD Society Brain Bank clinical diagnostic criteria at the RKU which is a specialized center for PD. Using a standard procedure peripheral venous blood in non-fasting state was collected with a Monovette™ blood drawing system (Sarstedt, Germany) and processed within 3 h post-collection. For isolation of peripheral blood leukocytes, EDTA was used as anticoagulant. Li-Heparin monovettes (Sarstedt, Germany) were used for the collection of whole blood for flow cytometry. For determination of peripheral blood levels of cytokines, serum collection tubes (Sarstedt, Germany) were used. Patients and healthy controls were age and sex matched. For age matching, both groups were designed to have no significant difference in age when comparing average, median and range. For sex matching, differences between investigated groups were no more than 10 % in advantage of either gender.
Staging of PD progression with Hoehn & Yahr staging system
To assess the progression of PD in patients, the modified Hoehn & Yahr staging system was used . A score of 0 indicates no detectable signs of disease and was assigned to all healthy controls. Disease progression is broken down to seven stages (including 1.5 and 2.5 in the modified version of the system) ranging from mild unilateral involvement (1.0) to confinement to wheelchair or bed (5.0).
Isolation of peripheral blood mononuclear cells and purification of peripheral blood monocytes
Peripheral blood mononuclear cells were isolated from venous whole blood by density centrifugation on Histopaque® density gradient. After two subsequent washes to get rid of contaminating platelets, cells were labeled with magnetic beads coupled to monoclonal antibodies against CD14 (Miltenyi Biotec, Germany) and CD14-positive cells separated in a column placed in a strong magnetic field (Miltenyi Biotec, Germany). Subsequently, the column was removed from the magnetic field and the retracted cells eluted with MACS™ buffer (Miltenyi Biotec, Germany). For untouched monocytes isolation, non-monocytes were labeled with biotin-conjugated antibodies against CD3, CD7, CD16, CD19, CD56, CD123 and Glycophorin A, and Anti-Biotin MicroBeads (Miltenyi Biotec, Germany). The flow-through fraction represents the unlabeled monocytes. Cells were then centrifuged at 300 g for 10 min at RT and resuspended in cell culture medium (RPMI 1640, 10 % FCS (PAA, Austria), 1 % penicillin/streptomycin (PAA, Austria) or RLT-lysis buffer (Qiagen, The Netherlands) for further applications. The purity of the isolated cell population was controlled by flow cytometry analysis and immunocytochemistry.
Monocyte culture and stimulation
To functionally characterize monocyte activation, monocytes were plated on uncoated culture plates (24-well, BD Biosciences, USA) at a density of 106 cells/ml (5.105 cells per 24-well). Monocytes were allowed to rest for 24 h prior to the LPS stimulation (1 ng/ml, ) to eradicate the influence of mechanical/chemical/temperature stress during the isolation procedure on experimental results. Monocytes were cultured in sterile RPMI 1640 medium supplemented with 10 % v/v fetal calf serum (FCS, PAA, Austria) and 1 % v/v penicillin–streptomycin (P/S; 1,000 U/ml, PAA, Austria). Sterile culture medium was used as a negative control for monocyte stimulation. LPS stimulation was performed in duplicates. After 24 h stimulation, the supernatant was collected and the cells were lysed with extraction lysis buffer (1 M NaCl, 0.6 % w/v sodium deoxycholate, 0.6 % v/v Igepal, 5 % v/v 1 M Tris pH 8.0, protease inhibitor cocktail (Roche, Switzerland)).
Cytokine quantification in cell culture supernatants
Cytokine levels in culture supernatants were quantified by ELISA (IL-6, IL-10, CCL2, IFNγ, IL-1β; all antibody pairs obtained from BioLegend, USA) or with an electrochemiluminescence immunoassay (TNFα, IFN-8; MesoScale Discovery, USA). Each standard and sample were measured by means of two replicates, average value calculated and blank absorption of matrix subtracted. A threshold of 0.2 coefficient of variance (CV) was set as a limit to consider a value significant. Absorption values of known standards were plotted against concentrations and the resulting sigmoidal curve fitted using non-weighted five-parameter logistics with ReaderFit™ (Hitachi Solutions, Japan). Cytokine release was normalized to cell number by quantification of protein concentration in cell lysate, measured by BCA assay (Thermo Scientific, USA) according to the supplier’s instructions.
Four milliliters of anticoagulated whole blood (Sarstedt, Germany) was collected in Li-Heparin monovettes from healthy volunteers and PD patients after informed consent. Osmotic lysis of red blood cells was performed with a red blood cell lysis buffer (RBC-LB: 50 mM NH4Cl, 70 mM NaHCO3, 0.1 % EDTA, dH2O). After lysis and washing with FACS buffer [PBS (Life Technologies) + 10 % FCS (PAA, Austria)], cells were resuspended in RPMI + 10 % FCS + 2 % P/S and treated 24 h or 48 h at 37 °C with vehicle control (PBS) or APG101 (250 µg/ml). After incubation cells were resuspended, washed with FACS buffer and stained with anti-human antibodies specific for anti-HLA-DR (1:200; Biolegend, USA, L243, Pe-Cy7), anti-CD14 (1:200; BD, USA; M5E2, PerCP-Cy5.5), anti-CD16 (1:10; BD, 3G8, PE), anti-CD2 (1:20; eBioscience, USA RPA-2.10, FITC), anti-CD335 (1:100; AbDSerotec, UK; 9E2, FITC), anti-CD15 (1:13; Miltenyi Biotec, VIMC6, FITC) and anti-CD19 (1:100; eBioscience, USA; HIB19, FITC) for 25 min at 4 °C in the dark. After washing, the stained cells were fixed 20 min in 2 % PFA, filtered (70 μm) and analyzed by flow cytometry (LSRII, BD) using appropriate color compensation to correct for spectral overlap and autofluorescence. Therefore, following isotype controls were used at the same concentration as the primary antibodies: mouse IgG2a, κ (Biolegend, USA MOPC-173, PE-Cy7), mouse IgG1, κ (eBioscience, USA, P188.8.131.52.1, FITC), mouse IgG2a, κ (BD, USA; G155-178, PerCP-Cy5.5), mouse IgG1, κ (BD, MOPC-21, PE). Monocytes are among HLA-DR+ cells that do not express B-cell (CD19−), T-cell (CD2−), NK-cell (CD335−), or granulocyte makers (CD15−). Within this gate, CD14+ CD16− and CD14+ CD16+ monocytes, CD14− CD16+ monocytes and CD14− CD16− DCs can be separated. To exclude cell doublets, cells were gated using area vs. width signal intensity. Data are presented as mean ± SEM from four independent experiments.
Next-generation sequencing and expression analysis
For whole-transcriptome analysis of expression, monocytes were isolated from the peripheral blood of healthy controls and PD patients as described above and lysed with RLT buffer (Qiagen, The Netherlands). After isolation of total RNA (miRNeasy Mini Kit, Qiagen, The Netherlands), 200 ng total RNA was used for the generation of mRNA-focused libraries (TruSeq RNA Sample Preparation Kit v2, Set B, Illumina, USA). Clusters were generated with cBot (Illumina, USA) with the TruSeq SR Cluster Kit v3-cBot-HS (Illumina, USA). Samples were sequenced on a HiSeq 2000 sequencing system (Illumina, USA) with TruSeq SBS Kit HS-v3 (50 cycles). 52 bases were sequenced with single read and 2.0–2.5 × 107 reads per sample, 7 bases IndexRead.
For the unsupervised hierarchical clustering of subjects based on gene expression, genes with average expression among all samples <5 FPKM were excluded. Cosine correlation and complete linkage were used for clustering with Genesis . Heatmaps and cluster diagrams were generated with Genesis. For pathway analysis, genes were filtered by expression level (≥5 in at least one of the two groups to be compared), log ratio (log2 ≥ 1 or ≤−1) and significance of the difference (q value, significance corrected for multiple testing by Benjamini Hochberg, q ≤ 0.05) between the compared groups. Canonical pathways and upstream regulators were predicted by an Ingenuity pathway analysis (Qiagen, The Netherlands); involved molecular functions and biological processes were identified with Genomatix genome analyser pathway system (Genomatix Software GmbH, Germany). For the identification of genes which are consistently expressed within the two groups to compare, we filtered out all genes whose expression pattern was determined by less than 25 % of the expression values. For heatmap generation, z scores were built for each value.
Total RNA was extracted using RNeasy Mini Kit (Qiagen, USA) in accordance with the manufacturer’s instructions. RNA concentration and quality were controlled using NanoDrop (ThermoScientific, Waltham, MA, USA) and 1 µg of total RNA was used to synthesize cDNA using Iscript reverse transcriptase (Bio-Rad Laboratories) containing oligo-dT primers and random primers. cDNA was then diluted ten times and PCR analysis was performed on a Bio-Rad iCycler System using iQSYBR Green Supermix. A specific standard curve was performed in parallel for each gene to assess the specificity of the products, for quantification of the respective transcripts in duplicate. PCR conditions were 3 min at 95 °C, followed by 40 cycles of 30 s at 94 °C and 10 s at 60 °C (for FASLG, 50 cycles of 20 s). The relative levels of each gene of interest were normalized to TBP, GAPDH (Fig. 5) and B2M (Fig. 2). Primers for FAS, FASLG and GAPDH were obtained from Qiagen. A list of all other primers used is provided in Supplementary Table 8.
Phagocytosis assay was performed as per supplier’s instructions with pHrodo™ Green Zymosan A BioParticles® (Life Technologies, Carlsbad, USA) conjugate for phagocytosis. In brief, monocytes were plated on a 96-well tissue culture plate and incubated in RPMI1640 10 % FCS 1 %P/S containing fluorescently labeled zymosan particles (0.5 mg/ml) for 4 h at 37 °C, 5 % CO2. Fluorescence was measured with Victor X3™ microplate reader (Perkin-Elmer, Waltham, USA).
Statistical analyses were carried out using GraphPad Prism version 6.02 for Windows, GraphPad Software, San Diego, CA, USA, “www.graphpad.com”. All values in the figures are presented as mean ± SEM unless stated otherwise. Outliers were identified by ROUT analysis with Q = 1 %. Gaussian distribution was tested with D’Agostino and Pearson omnibus normality test, Shapiro–Wilk normality test and KS normality test. Variances were compared with F test. Unpaired t test with (unequal SD) or without (equal SD) Welch’s correction was used for unpaired data and paired t test for paired data from Gaussian distribution. Mann–Whitney test (unpaired data) or Wilcoxon matched-pairs signed-rank test (paired data) was used for data from non-Gaussian distribution. All tests for significance were two tailed.
Enrichment of classical CD14+CD16− monocytes in peripheral blood of PD patients
PD monocytes exhibit a dysregulation of inflammatory pathways
A detailed analysis based on filtering genes by expression and significant difference between the disease and control groups revealed that genes which are differentially expressed in PD monocytes include transcription factors, secreted proteins and micro-RNAs (Fig. 2c, d).
Top 5 differentially regulated canonical pathways in PD monocytes (ingenuity pathway analysis)
Ingenuity canonical pathways
p value of overlap
Granulocyte adhesion and diapedesis
Agranulocyte adhesion and diapedesis
Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F
Differential regulation of cytokine production in intestinal epithelial cells by IL-17A and IL-17F
IL-17A signaling in fibroblasts
Top 5 predicted upstream regulators in PD monocytes (ingenuity upstream analysis)
p value of overlap
Target molecules in dataset
ATF3, CCL2, CCL3, CCL4, CD83, CD9, COL1A2, COL6A1, CTSK, CXCL1, CXCL2, DCN, DKK3, DUSP1, DUSP2, EGR1, EGR2, FOS, FOSB, G0S2, GPR183, HCAR3, HLA-DQA1, IGFBP4, IL1B, IL8, JUN, KLF4, KLF6, MME, MMP2, MMP9, NFKBIA, NFKBIZ, NR4A1, NR4A2, OLR1, PLIN2, PMAIP1, PPP1R15A, PTGS2, RGS1, RHOB, SERPINH1, SLAMF7, SPARC, TGM2, TNC, TPM2, TRIB1, ZFP36
ATF3, CCL2, CXCL2, DCN, DUSP1, EGR1, EGR2, FHL1, FOS, FOSB, GPR183, IER2, IGFBP4, IL1B, IL8, JUN, KLF6, MMP2, MMP9, NR4A1, NR4A2, OLR1, PPP1R15A, PTGS2, RGS1, RHOB, SCD, TGM2, TNC, TRIB1, ZFP36
CCL2, CCL3, CCL4, CD83, CLU, COL1A2, COL6A1, COL6A2, CTSK, CXCL1, CXCL2, DCN, DKK3, DUSP1, ECM1, EGR1, EGR2, EMILIN1, FHL1, FOS, FOSB, HLA-DQA1, IER2, IGFBP4, IL1B, IL8, JUN, KLF4, LTBP2, MMP2, MMP9, NFKBIA, NR4A1, NR4A2, OLR1, PTGS2, RGCC, RHOB, SCD, SERPINH1, SERTAD1, SPARC, TGM2, TNC, TPM2, ZFP36
ATF3, CCL2, CCL3, CCL4, CTSK, CXCL2, DUSP1, DUSP2, EGR1, FOS, FOSB, G0S2, GPR183, IGFBP4, IL1B, IL8, JUN, MMP2, MMP9, NR4A1, NR4A2, OLR1, PLIN2, PMAIP1, PTGS2
CCL2, CCL3, CCL4, CD83, COL1A2, COL6A1, CXCL1, CXCL2, DUSP10, EGR1, EGR2, FOS, FOSB, GPNMB, HCAR3, IL1B, IL8, JUN, MME, MMP9, NFKBIA, NR4A1, NR4A2, PLIN2, PPP1R15A, TNC, TRIB1, ZFP36
In accordance with the next-generation sequencing results from the PD discovery cohort, we could confirm by qRT-PCR in a separate validation cohort of 14 PD patients and 13 controls the highly significant downregulation of six mRNAs: JUN, EGR1, DUSP1, RHOB, FOS, NFKBIZ and a tendency for downregulation for FOSB (Fig. 2e).
PD monocytes are pathologically hyperactive in response to LPS stimulation and their hyperactivity is correlated to PD severity
We hypothesized that if monocyte hyperactivation upon LPS challenge is pathophysiologically relevant, the extent of monocyte hyperactivation should be reflected in clinical parameters. Indeed, we found that IL-6 secretion from LPS-stimulated monocytes derived from PD patients was strongly positively correlated with the Hoehn & Yahr (H&Y) stage of disease severity (Fig. 3h).
To further characterize the functional abnormalities of isolated PD monocytes, we assessed another main function of myeloid phagocytes—the phagocytosis of extracellular material. To this end, we applied a highly specific phagocytosis assay employing pH-sensitive-labeled yeast wall particles exhibiting a weak fluorescence at neutral pH and a dramatic increase in fluorescence at lower pH. This enables the quantification of cellular uptake and acidification of the phagocytic compartments. FACS analysis and microscopic pictures at the cellular level confirm the uptake of fluorescent particles (Supplementary Fig. 4). Using this phagocytosis assay, we found a significant reduction in phagocytic activity in the monocytes of PD patients compared to those of healthy controls (Fig. 3i).
The CCR2–CCL2 axis is activated in PD
To investigate whether the observed inflammatory dysregulation is specific for PD we also included patients with other parkinsonian symptoms like patients with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) in our study. FACS-based analysis of monocytic subpopulations revealed an enrichment of classical monocytes also in PSP and MSA patients (Supplementary Fig. 5b), whereas the number of total monocytes was not significantly altered between the PD, PSP, MSA and control group (Supplementary Fig. 5a). LPS stimulation of cultured monocytes from PD patients and controls leads to an excess release of IL-6 from PD monocytes compared to controls as observed in our initial experiments. However, we also observed increased IL-6 release from PSP monocytes compared to controls. In contrast, MSA monocytes did not release excess IL-6 upon LPS stimulation (Supplementary Fig. 5c). Regarding phagocytic activity of cultured monocytes, we found only reduced phagocytic activity in PD monocytes. PSP and MSA monocytes had similar phagocytic activity than control monocytes (Supplementary Fig. 5d). We also measured CCL2 levels in the serum of PSP and MSA patients with no significant differences compared to control serum, whereas PD serum showed increased CCL2 levels (Supplementary Fig. 5e).
FAS/FASLG system is involved in the dysregulation of monocyte subpopulations in PD patients
Using a multimodal approach, we identified a dysregulation of peripheral human monocytes in PD. We have shown that PD monocytes have a pro-inflammatory predisposition based on their transcriptome profile and disbalance of monocytic subpopulations. The increased ratio in pro-inflammatory classical monocytes in PD patients was accompanied by an activation of the CCR2–CCL2 axis in PD. Moreover, using a human primary monocyte culture system we were able to demonstrate that PD monocytes respond to a “second hit” with hyperactivation, which correlated with clinical disease stages. Finally, we demonstrate that the FAS/FASLG system is essentially involved in deregulation of monocyte subpopulations, which can be pharmacologically reverted by neutralization of FASLG.
In the transcriptome analysis, we found that the response to inflammatory triggers is dysregulated on a transcriptional level in PD. This dysregulation could also be confirmed in an independent cohort on the basis of the single genes JUN, FOSB, EGR1, DUSP1, RHOB, FOS and NFKBIZ. Thus, PD monocytes were preconditioned to behave abnormally upon inflammatory stimulation. However, our work was not designed as a classical biomarker study. We did not investigate the correlation of mRNA levels of specific genes in monocytes and disease severity. This would possibly require larger and or more homogenous PD patient cohorts including, for example, the exclusion of specific mutations in PARK genes. Nevertheless, the findings of this study could be the basis for the development of easily accessible PD biomarkers in the blood of PD patients and might turn out to be valuable readouts to judge future clinical studies on disease-modifying therapies. In a complementary approach using a FACS-based technology, we were able to confirm a pro-inflammatory dysregulation of monocytic subpopulations.
These primary abnormalities of PD monocytes suggest that monocytes from PD patients also behave functionally different, supported by an impaired phagocytic function of PD monocytes (this study and ). Since monocyte-derived CNS macrophages can contribute to the resolution of neuroinflammation by clearing of cell debris and extracellular material , a decrease of phagocytic activity could be detrimental. Additional proof for functional abnormalities of monocytes in PD patients comes from our primary human monocyte culture system. Unlike the study of Hasegawa et al. , we found functional overactivity upon LPS stimulation of cultured monocytes from PD patients compared to healthy controls. The discrepancy to the study of Hasegawa et al. who found lower levels of certain cytokines (IL-1β, TNFα, IL-6 and IFNγ) released by PBMCs might be explained by the monocyte isolation method. While Hasegawa et al. used gradient density sedimentation leading ultimately to the isolation of monocytes and lymphocytes (contained in the PBMC fraction), we used positive magnetic selection based on CD14 expression leading to the isolation of solely monocytes. Additionally, when Hasegawa et al. enriched monocytes in culture by changing the media they could not confirm decreased cytokine release in their cultures suggesting that the lymphocytes contained in the culture of Hasegawa et al. and the isolation method account for the discrepancy of the two studies. Strikingly, increased cytokine secretion from PD monocytes upon LPS stimulation correlated in our study with PD disease state, thereby suggesting that monocyte hyperactivation is linked to disease severity. Collectively, our findings indicate that myeloid cells of the innate immune system are functionally altered and point to a pro-inflammatory predisposition of the innate immune system of PD patients.
Most importantly, PD monocytes were not functionally overactive a priori but required a “second hit” to exert their abnormal activity. Such “second hits” could be environmental cues or CNS factors triggering the peripheral immune system. Strong support for this theory comes from the study of Gao et al. , who showed that LPS-induced inflammation and alpha-synuclein pathology act synergistically and potentiate neurodegeneration in a genetic mouse model of PD. Similarly, recent studies demonstrated that repeated LPS injections exacerbated the pathogenesis of ALS in a mouse model system  and impaired the behavioral phenotype in prion-diseased animals . Our results suggest that the progression or development of neurological diseases might be affected by the number and type of environmental second hits in conjunction with an existing predisposition. Our data from PD monocytes and previous experimental evidence are complemented by the association of influenza infections, asthma and allergic rhinitis to the development of PD [7, 26]. Our data might also provide an explanation for the clinical observation that PD patients often do not fully recover from worsened PD symptoms after severe systemic infections. However, further studies are needed to translate our findings to clinical therapies.
The increase of classical CD14+CD16− monocytes and decrease in the non-classical CD14−CD16+ monocytes in the blood of PD patients observed in this study could result from both differentiation of monocytes and monocyte precursors to the classical pro-inflammatory phenotype or from increased migration from the bone marrow. Support for the latter comes from our observation of elevated levels of CCL2 in the serum of PD patients, a classical signal for recruitment of monocytes from the bone marrow . In agreement with this idea, Funk et al. demonstrated an upregulation of surface CCL2 receptor (CCR2) on classical monocytes of PD patients . The elevated serum levels of CCL2 in PD could possibly be attributed to the increased production of the chemokine by monocytes themselves. In line with this, we found that upon LPS stimulation, PD monocytes secrete significantly higher levels of CCL2 compared to control monocytes. Together, these results suggest that the CCR2–CCL2 axis ranging from CCL2 release to altered composition of monocytes is activated in PD. These results are also in agreement with previous studies [6, 35] demonstrating elevated LPS-induced CCL2 production from PD monocytes. CCL2 release by monocytes could be a part of a feedback loop serving to enhance the further recruitment of monocytes to the inflammatory site. Interestingly, activated microglia can also secrete CCL2 , which can cross the blood–brain barrier and recruit monocytes into the inflamed CNS. Reactive microgliosis has been observed in the affected PD brain regions and is hypothesized to be triggered by extracellular alpha-synuclein and apoptotic neurons . Thus, the increased CCL2 serum levels and increase of classical monocytes in our PD cohort could possibly also be a result of the secretion of inflammatory mediators by microglia.
To gain more insight in the specificity of the observed dysregulation of peripheral human monocytes in PD, we also included PSP and MSA patients as another disease cohort with parkinsonian symptoms. Overall, we found evidence for inflammatory dysregulation also in PSP and MSA with regard to some aspects (enrichment of classical monocytes, increased IL-6 release upon LPS stimulation for the PSP cohort), while other changes are clearly specific for PD (decreased phagocytic activity, increased CCL2 serum levels for MSA). However, it has to be taken into account that due to the limited number of MSA and PSP patients a definitive statement regarding inflammatory dysregulation in PSP and MSA remains difficult. Further studies including larger patient numbers for MSA and PSP are needed to fully understand the biology of peripheral monocytes in MSA and PSP.
Three pieces of evidence in our study suggest an essential involvement of the FAS/FASLG system in the dysregulation of PD monocytes. First, we found a strong upregulation of both FAS and FASLG in monocytes from PD patients. Second, the transcriptome gene set enrichment analysis identified FAS as a top upstream regulator of dysregulated genes in PD monocytes. Finally, pharmacological neutralization of FASLG could reverse the increased ratio of classical to non-classical monocytes in PD patients and controls in vitro suggesting that the FAS/FASLG system plays a crucial role in the regulation of human monocyte subpopulations. Our results are also in line with the findings of Brochard et al.  describing an FASLG-dependent dopaminergic toxicity in MPTP-treated mice. Neutralization of FASLG could hold a therapeutic promise, and clinical studies based on the FASLG neutralizing fusion protein used in our study (APG101) are clearly warranted. Importantly, APG101 has already been successfully applied to patients and turned out to be safe in a neuro-oncological context . However, further studies are needed to fully translate our findings into clinical therapies.
In summary, our findings provide the first direct evidence that circulating myeloid cells are altered in terms of their transcriptome profile, subset composition, and function in PD patients. Furthermore, we present the FAS/FASLG system as a regulator of monocyte subpopulations which could be targeted in pharmacological approaches to treat PD. A better understanding of monocyte function and the role of the FAS/FASLG system as well as first safety and proof-of-principle studies in PD patients using APG101 may pave the way to novel therapies aimed at halting disease progression in PD patients.
We thank O. Hill and M. Thiemann M (Apogenix GmbH, Heidelberg 69120) for providing APG101. We thank Dorothea Hüske, Isabell Hafner and Sandra Schüle for organizing the collection of samples and patient data. We thank Jasmin Haderspeck for technical assistance. This research was supported by funds from the Baustein Program Medical Faculty Ulm University (VG, KMD), Charcot Foundation (ACL, JHW) and Thierry Latran Foundation (LZ, JHW).
Conflict of interest
The authors declare that they have no conflict of interest.
- 18.Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Hoglinger GU (2012) Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol 238:183–191. doi: 10.1016/j.expneurol.2012.08.020 PubMedCrossRefGoogle Scholar
- 22.Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS (2011) Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 119:807–814. doi: 10.1289/ehp.1003013 PubMedCrossRefPubMedCentralGoogle Scholar
- 42.Wissemann WT, Hill-Burns EM, Zabetian CP, Factor SA, Patsopoulos N, Hoglund B, Holcomb C, Donahue RJ, Thomson G, Erlich H, Payami H (2013) Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet. 93(5):984–993. doi: 10.1016/j.ajhg.2013.10.009
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.